← Library
PT-141 (Research Grade)
Research Use
Also known as Palatin precursor
Function
Primary
Sexual dysfunction (men & women) · Libido enhancement
Mechanism
MC3R/MC4R agonist — centrally activates hypothalamic melanocortin pathways; enhances sexual arousal independent of hormonal levels.
Evidence
Pre-clinical / Observational
Research
Phase II/III data led to Vyleesi approval
Dosing
Range
0.5–2 mg PRN
Frequency
As needed (max 1×/24h)
Route
Subcutaneous · Intranasal
Cycling
PRN only.
Benefits
- ·On-demand libido enhancement in both sexes
- ·Centrally mediated, hormone-independent
Risks
- ·Nausea
- ·Flushing
- ·Transient BP elevation
- ·Compounded purity concerns
Contraindications
- ·Uncontrolled hypertension
- ·Cardiovascular disease
Regulatory
Research-grade not FDA-approved; FDA-approved analog = Vyleesi (bremelanotide)
Functional Groups
Cited Works
- Diamond LE et al. PT-141, a melanocortin agonist for sexual dysfunction. Int J Impot Res. 2004;16:51.